PAVM News and Press, PAVmed Inc. From 12/15/22

Executes first commercial contract with leading New Jersey oncology practice PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, toda...

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that the Compan...

EsoCheck esophageal cell sampling procedure performed on 687 patients with 98% success rate Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: P...

PAVmed Inc. (PAVM) Q3 2022 Earnings Conference Call November 15, 2022 04:30 PM ET Company Participants Adrian Miller - VP, IR Lishan Aklog - Chairman and CEO Dennis McGrath - President and CFO Conference Call Participants Charlie Montang - Lake Street...

PAVmed press release ( NASDAQ: PAVM ): Q3 GAAP EPS of -$0.29. PAVmed had cash and cash equivalents of $56.8 million as of September 30, 2022, compared to $77.3 million as of December 31, 2021. For further details see: PAVmed GAAP EPS of -$0.29

EsoGuard test volume shows steady sequential growth Veris Cancer Care Platform poised for commercial launch Conference call and webcast to be held today at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVm...

PAVmed ( NASDAQ: PAVM ) is scheduled to announce Q3 earnings results on Tuesday, November 15th, after market close. The consensus EPS Estimate is -$0.23 and the consensus Revenue Estimate is $0.23M. Over the last 2 years, PAVM has beaten EPS estimates 63% of the ti...

EsoGuard test volume increased 28% sequentially and 436% annually Conference call and webcast to be held today at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer preventi...

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”, the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D. , PAVmed&#...

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced tha...